CN116672332A - Application of L-theanine in preparation of angiogenesis promoter - Google Patents

Application of L-theanine in preparation of angiogenesis promoter Download PDF

Info

Publication number
CN116672332A
CN116672332A CN202310581049.XA CN202310581049A CN116672332A CN 116672332 A CN116672332 A CN 116672332A CN 202310581049 A CN202310581049 A CN 202310581049A CN 116672332 A CN116672332 A CN 116672332A
Authority
CN
China
Prior art keywords
theanine
angiogenesis
ischemic
promoter
ischemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310581049.XA
Other languages
Chinese (zh)
Inventor
胡新央
王静宜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang University ZJU
Original Assignee
Zhejiang University ZJU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang University ZJU filed Critical Zhejiang University ZJU
Priority to CN202310581049.XA priority Critical patent/CN116672332A/en
Publication of CN116672332A publication Critical patent/CN116672332A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)

Abstract

The invention relates to the field of biological medicine, and discloses application of L-theanine in preparation of a angiogenesis promoter. According to the invention, the experiment shows that the L-theanine can promote the angiogenesis after ischemia for the first time, and is expected to provide a new theoretical basis and a potential intervention target point for the treatment of the angiogenesis after ischemia.

Description

Application of L-theanine in preparation of angiogenesis promoter
Technical Field
The invention relates to the field of biological medicine, in particular to application of L-theanine in preparation of a angiogenesis promoter.
Background
Ischemic diseases have a tendency to rise year by year in incidence and death rate in China, including myocardial ischemia, cerebral ischemia and vascular diseases of lower limbs. Ischemic disease refers to the occurrence of constriction or occlusion of blood vessels under various pathological conditions, and is one of refractory diseases seriously jeopardizing human health. Abrupt interruption of the blood supply can lead to temporary or permanent oxygen and nutrient deficiency. Thus, cell death and tissue damage follow, depending primarily on the extent and duration of ischemic injury. Angiogenesis plays an important role in the development and evolution of ischemic diseases, and determines the prognosis of ischemic diseases to a large extent. Under the stress of ischemia and hypoxia, the new blood vessel generated by the body itself often cannot effectively compensate for the ischemia state. In this case, therapeutic angiogenesis is a new strategy for treating ischemic diseases. Therefore, the improvement of the ischemic state of local tissues is one of the key scientific problems, while the full disclosure of the regulation mechanism of angiogenesis in ischemic diseases is a scientific problem to be solved urgently so far, but the specific molecular mechanism for regulating angiogenesis under the ischemic condition is not completely clear so far.
L-Theanine (L-Theanine), also known as glutamic acid gamma-ethylamide, is a unique free amino acid in tea. L-theanine is similar in chemical structure to the active substance glutamine, glutamic acid in the brain. In humans, synthetic L-theanine is produced mainly by using glutaminase from L-glutamine and ethylamine in foods as a racemic mixture of D-and L-forms. It can then be directly excreted by urine, or can be excreted by urine after hydrolytic decomposition of amino groups in the kidneys into glutamic acid and ethylamine. The current international research on L-theanine mainly focuses on the aspects of reducing subjective stress response, improving cognitive ability, optimizing sleep and the like, and possibly has a protective effect on obesity and common cold. The invention reveals that the L-theanine can promote angiogenesis of the lower limb after ischemia, and no report on the aspect of regulation and control of the L-theanine on the angiogenesis exists internationally at present, so that the invention is expected to provide a new theoretical basis and potential intervention targets for the treatment of the angiogenesis after ischemia.
Disclosure of Invention
In order to solve the technical problems, the invention provides application of L-theanine in preparing a angiogenesis promoter. According to the invention, the experiment shows that the L-theanine can promote the angiogenesis after ischemia for the first time, and is expected to provide a new theoretical basis and a potential intervention target point for the treatment of the angiogenesis after ischemia.
The specific technical scheme of the invention is as follows:
in a first aspect, the present invention provides the use of L-theanine in the preparation of an angiogenesis promoting agent.
Preferably, the angiogenesis promoter is an angiogenesis promoter for promoting angiogenesis in lower limbs, cardiac muscle and brain.
In a second aspect, the invention provides the use of L-theanine in the manufacture of a medicament for the treatment of ischemic disease.
Preferably, the ischemic disease includes lower limb vascular disease, myocardial ischemia, and cerebral ischemia.
Preferably, the ischemic disease treatment drug comprises: l-theanine as a main active ingredient, and a pharmaceutically acceptable carrier and/or excipient.
Further, the ischemic disease therapeutic drug is a pharmaceutical preparation administered by injection.
Further, the injection is subcutaneous or intravenous.
In a third aspect, the present invention provides an angiogenesis promoting agent comprising L-theanine.
Preferably, the angiogenesis promoter is an angiogenesis promoter for promoting angiogenesis in lower limbs, cardiac muscle and brain.
Preferably, the angiogenesis promoter further comprises a pharmaceutically acceptable carrier and/or excipient.
Compared with the prior art, the invention has the beneficial effects that:
the invention discovers through experiments that L-theanine can promote angiogenesis after ischemia for the first time, and specifically: the invention discovers that the L-theanine can obviously increase the number of blood vessels after ischemia; l-theanine can significantly enhance the lumen formation ability of endothelial cells after ischemia; l-theanine can significantly improve the budding ability of endothelial cells after ischemia. The new discovery of the invention is expected to provide a new theoretical basis and potential intervention targets for post-ischemic angiogenesis treatment.
Drawings
FIG. 1 is a graph showing Doppler blood flow monitoring of mice injected intraperitoneally with L-theanine (1 mg/kg) and PBS, respectively, 0, 3, 7, and 14 days after lower limb ischemia; wherein: a: doppler blood flow detection results of the ischemic lower limbs and the non-ischemic lower limbs of the mice; b: statistics of the blood flow perfusion ratio (ROI%) of the two groups of ischemic and non-ischemic lower limbs p <0.05 NC versus L-theanine;
FIG. 2 is a gastrocnemius section immunofluorescence of L-theanine (1 mg/kg) and PBS respectively injected intraperitoneally into mice 14 days after lower limb ischemia; wherein: a: immunofluorescence results of a negative control group and an L-theanine injection group after lower limb ischemia of the mice, wherein red is isolectinB4 (iB 4) which represents vascular endothelial cells; blue is nuclear DAPI; b: statistical results of two groups of new blood vessels, < p <0.05 NC versus L-theanine;
FIG. 3 is a luminal formation experiment of L-theanine (1. Mu.M), PBS after endothelial cell treatment, respectively; wherein: lumen formation representative figures of control group and L-theanine treatment group; b: quantitative statistics of the length of the main pipe cavity; n=6, data are mean ± SEM; * P <0.01, NC versus L-theanine;
FIG. 4 shows budding experiments after treatment of endothelial cells with L-theanine (1. Mu.M) and PBS, respectively; wherein: budding representative plots for control and L-theanine treatment groups; b: quantitative statistics of total budding length and budding quantity; n=6, data are mean ± SEM; * P <0.05, < P <0.01, nc versus L-theanine.
Detailed Description
The invention is further described below with reference to examples.
General examples
An angiogenesis promoting agent comprising L-theanine and optionally further comprising a pharmaceutically acceptable carrier and/or excipient. Preferably, the angiogenesis promoter is an angiogenesis promoter for promoting angiogenesis in lower limbs, cardiac muscle and brain.
A therapeutic agent for ischemic diseases, comprising: l-theanine as a main active ingredient, and a pharmaceutically acceptable carrier and/or excipient. Preferably, the ischemic disease includes lower limb vascular disease, myocardial ischemia, and cerebral ischemia. Further, the ischemic disease therapeutic drug is a pharmaceutical preparation administered by injection. The injection is subcutaneous or intravenous.
Example 1
(one) establishment of mouse lower limb ischemia model
(1) Weighing and anaesthetizing: c57 mice with the size of 10 weeks are taken, anesthetized by intraperitoneal injection of ketamine/hydroxylazine (80/5 mg/kg), placed on a constant temperature heating blanket after the mice lose mobility, fixed on a fixed plate after the mice are completely anesthetized, and the whole fixed plate is placed on the constant temperature heating blanket to maintain the body temperature.
(2) Dehairing: dehairing is performed one day in advance on the left lower limb.
(3) Isolation of femoral artery: the groin cuts the skin and the blunt dissection is fully exposed, and the nerve is gently pulled off under a split microscope to separate the femoral vein from the nerve.
(4) Ligating; both the proximal and distal portions of the femoral artery and vein were ligated with 7-0 sutures. The branch between the two is ligated and all blood vessels in the middle are excised.
(5) Stitching: the muscle tissue is gently reset, subcutaneous tissues are aligned and then the skin is intermittently sewn, the tension is reduced, and the sterilization is performed.
(6) Waking up: the mice were placed on a thermostatic heating blanket at 37 ℃ waiting to wake up.
(7) Lower limb blood flow perfusion detection: anesthesia was performed with intraperitoneal ketamine/hydroxylazine (80/5 mg/kg) and placed on a heating blanket to maintain body temperature, prone on a test table, double lower limb blood flow at days 0, 3, 7 and 14 post-surgery was detected with a noninvasive laser doppler flow meter, data recorded, and ischemic and non-ischemic lower limb blood flow perfusion ratios (ROI%) were calculated.
(8) Administration: PBS and L-theanine (1 mg/kg) were injected intraperitoneally.
(II) material selection: after 14 days post-operation, after anesthesia with chloral hydrate, the limbs were fixed in the supine position and the myocardium perfused until the liver became white, and the lower limb gastrocnemius muscle was collected.
(III) gastrocnemius vascular staining: the calf muscle tissue of the lower limb was embedded and frozen into sections, and the degree of angiogenesis was evaluated by staining.
Frozen tissue sections were fixed in 10% formaldehyde for 8 hours and permeabilized with 0.5% TRITON X-100 in PBS. After blocking with PBS containing 7% bovine serum albumin, sections were incubated with iB overnight at 4 ℃. Nuclei were stained with DAPI.
(IV) experimental results:
(a) The recovery rate of blood perfusion of the mice of the L-theanine administration group is higher than that of the mice of the control group: the ratio of ischemic lower limb and non-ischemic lower limb blood flow (ROI%) of the mice is shown in fig. 1, and the results show that the ratio of ischemic lower limb and non-ischemic lower limb blood flow (ROI%) of L-theanine is higher than that of the control group mice.
(b) The number of blood vessels in the left gastrocnemius muscle of the mice of the L-theanine administration group is significantly greater than that of the mice of the control group of the same sex at the same age: immunofluorescence of left lower limb gastrocnemius section of mice in the administration group is shown in FIG. 2, and the result shows that gastrocnemius blood vessels of the mice in the L-theanine administration group are increased compared with those of the mice in the control group. In the figure, red is iB4, which represents a new blood vessel, and blue is DAPI, which represents a nucleus.
Example 2
First lumen formation experiment
(1) Matrigel was thawed one day in a 4 degree celsius refrigerator and the middle gun head and 96 well plate were pre-chilled in a four degree celsius refrigerator.
(2) Thawed Matrigel was added to 96-well plates (placed on ice) with 50 μl per well, spread evenly, and avoid the generation of air bubbles. Then placed at 37 degrees Celsius, 5% CO 2 Is incubated for 30min.
(3) Endothelial cells were seeded with 100 μl of culture system per well at a density of 20,000 cells per well. At this time, PBS or L-theanine (1. Mu.M) was added to the medium in the required experiments.
(4) After incubation for 12 hours, the presence of the tubular structure was photographed with a light mirror (5 x, leica DM 3000). The total length of the tube was calculated using Image-Pro Plus software.
(II) budding experiment
(1) Preparation of hanging drops: after washing endothelial cells twice with PBS, cells were digested from the cell culture plate with EDTA-trypsin. Cells were centrifuged at 1000rpm for 5 min, the supernatant discarded and the cells resuspended in complete cell culture medium using PBS containing 10% fetal bovine serum for neutralization and digestion. The cell mass was then counted with a hemocytometer. Each experimental condition required 2 ten thousand cells. In view of the followingThe loss of cells throughout the process was calculated to ensure an additional 2 ten thousand cells, a total of 4 ten thousand cells per group for hanging drop preparation. Thereafter, 8 ten thousand cells were transferred to a fresh 15 ml centrifuge tube, and cell culture medium (containing carboxymethyl cellulose) was added to a total volume of 4 ml. The solutions were carefully mixed and transferred to 15 cm petri dishes with 30 μl of solution per well using a 12 channel sterile line gun, taking care to avoid air bubbles. To form spheres, the dishes were inverted at 37 ℃ and 5% CO 2 Culturing in an incubator for 24 hours.
(2) A carboxymethyl cellulose solution containing 20% fetal bovine serum was prepared one day in advance and was required the next day. Carefully mix, avoiding air bubbles.
(3) Before continuing the procedure, it should be checked whether the overnight cultured cell mass successfully formed spheroids, and if a plurality of small cell masses were formed rapidly, the next experiment could not be performed.
(4) 10x Medium 199,0.2N NaOH and carboxymethyl cellulose solution with 20% fbs and rat tail gum were placed on ice.
(5) Using a 10ml sterile pipette, 10ml PBS was aspirated, the hanging droplets (containing the spheres) were gently rinsed off, and the solution was transferred to a 15 ml centrifuge tube, the whole procedure was carefully handled, and the spheres were prevented from blowing off. It was centrifuged at 200. 200 g for 5 minutes at room temperature. The supernatant was then carefully aspirated to avoid bumping into the spheres, and a 20% fbs solution of carboxymethyl cellulose was added and carefully blown down.
(6) Preparing a rat tail gum culture medium: 4ml of rat tail gum was mixed with 0.5 ml 10x medium 199 on ice and then adjusted to pH by dropwise addition of ice bath 0.2N sterile sodium hydroxide solution. The tube was then carefully inverted to ensure adequate mixing. On this basis, a small amount of sodium hydroxide is added each time until the pH value of the rat tail gum culture medium changes from yellow to orange (total amount is about 250-500 μl). Note that in the whole process of adjusting pH, the rat tail gum medium should be placed on ice to prevent collagen from polymerizing.
(7) 2 ml of rat tail media from step (6) was added to the spheres in resuspended 20% FBS in carboxymethyl cellulose. Care should be taken to mix the solutions throughout the process to avoid air bubbles.
(8) 0.5 ml of the ball rat tail solution was added to each well of the 48-well plate. The cells were incubated in a cell incubator at 37℃and 5% CO2 for 20 hours.
(9) 1 ml of 10% paraformaldehyde was added to the 48-well plate and the plates were stored at 4 ℃ to stop the germination test.
L-theanine (1. Mu.M) or an equivalent amount of negative control (PBS) was added to the medium. After fixation, images were taken under an optical microscope (10 x, leica DM 3000). The cumulative length of sprouting and branching for each sphere was analyzed using Fiji/ImageJ analysis software.
(III) experimental results:
(a) The ability of endothelial cells to form tubes in the group administered with L-theanine was superior to that in the control group: the lumen forming ability of the control group and the L-theanine-treated group is shown in FIG. 3, and the results show that the lumen forming ability is enhanced after L-theanine treatment of endothelial cells as compared with the control group.
(b) The budding ability of endothelial cells of the L-theanine administration group is superior to that of the control group: the budding ability of the control group and the L-theanine-treated group is shown in FIG. 4, and the results show that the budding ability of the L-theanine-treated endothelial cells is enhanced as compared with the control group.
The raw materials and equipment used in the invention are common raw materials and equipment in the field unless specified otherwise; the methods used in the present invention are conventional in the art unless otherwise specified.
The foregoing description is only a preferred embodiment of the present invention, and is not intended to limit the present invention, and any simple modification, variation and equivalent transformation of the above embodiment according to the technical substance of the present invention still fall within the scope of the technical solution of the present invention.

Claims (10)

  1. Use of l-theanine in the preparation of a angiogenesis promoter.
  2. 2. The use according to claim 1, wherein: the angiogenesis promoter is used for promoting angiogenesis of lower limbs, cardiac muscle and brain.
  3. Application of L-theanine in preparing medicament for treating ischemic diseases.
  4. 4. A use according to claim 3, wherein: the ischemic diseases comprise lower limb vascular diseases, myocardial ischemia and cerebral ischemia.
  5. 5. A use according to claim 3, wherein: the ischemic disease therapeutic agent comprises: l-theanine as a main active ingredient, and a pharmaceutically acceptable carrier and/or excipient.
  6. 6. Use according to claim 3 or 5, characterized in that: the ischemic disease therapeutic drug is an injection preparation.
  7. 7. The use according to claim 6, wherein: the injection is subcutaneous or intravenous.
  8. 8. An angiogenesis promoter, characterized in that: including L-theanine.
  9. 9. The angiogenesis promoting agent according to claim 8, wherein: the angiogenesis promoter is used for promoting angiogenesis of lower limbs, cardiac muscle and brain.
  10. 10. The angiogenesis promoting agent according to claim 8, wherein: the angiogenesis promoter also comprises a pharmaceutically acceptable carrier and/or excipient.
CN202310581049.XA 2023-05-22 2023-05-22 Application of L-theanine in preparation of angiogenesis promoter Pending CN116672332A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310581049.XA CN116672332A (en) 2023-05-22 2023-05-22 Application of L-theanine in preparation of angiogenesis promoter

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310581049.XA CN116672332A (en) 2023-05-22 2023-05-22 Application of L-theanine in preparation of angiogenesis promoter

Publications (1)

Publication Number Publication Date
CN116672332A true CN116672332A (en) 2023-09-01

Family

ID=87789978

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310581049.XA Pending CN116672332A (en) 2023-05-22 2023-05-22 Application of L-theanine in preparation of angiogenesis promoter

Country Status (1)

Country Link
CN (1) CN116672332A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09286727A (en) * 1996-04-23 1997-11-04 Itouen:Kk Glutamic acid antagonist and preventive for nerve cell death
JP2000229854A (en) * 1999-02-15 2000-08-22 Ito En Ltd Intracerebral administering agent for treatment and prophylaxis of ischemic neurocyte apoptosis, intracerebral administering agent for treatment and prophylaxis of vascular dementia and administering agent in intracerebral surgery
CN1957933A (en) * 2005-10-31 2007-05-09 陈建操 Application of theanine in preparing medication of curing sequela of apoplexy or convalescent period of apoplexy
CN101849931A (en) * 2009-04-02 2010-10-06 陈建操 Medicament for treating encephalatrophy or encephalatrophic dementia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09286727A (en) * 1996-04-23 1997-11-04 Itouen:Kk Glutamic acid antagonist and preventive for nerve cell death
JP2000229854A (en) * 1999-02-15 2000-08-22 Ito En Ltd Intracerebral administering agent for treatment and prophylaxis of ischemic neurocyte apoptosis, intracerebral administering agent for treatment and prophylaxis of vascular dementia and administering agent in intracerebral surgery
CN1957933A (en) * 2005-10-31 2007-05-09 陈建操 Application of theanine in preparing medication of curing sequela of apoplexy or convalescent period of apoplexy
CN101849931A (en) * 2009-04-02 2010-10-06 陈建操 Medicament for treating encephalatrophy or encephalatrophic dementia

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JAMILA H等: "l -Theanine promotes nitric oxide production in endothelial cells through eNOS phosphorylation", HE JOURNAL OF NUTRITIONAL BIOCHEMISTRY, vol. 24, no. 3, pages 595, XP028986413, DOI: 10.1016/j.jnutbio.2012.02.016 *
JINGLIAN YAN 等: "Tetrahydrobiopterin, l-Arginine and Vitamin C Act Synergistically to Decrease Oxidative Stress, Increase Nitric Oxide and Improve Blood Flow after Induction of Hindlimb Ischemia in the Rat", MOLECULAR MEDICINE, vol. 18, no. 4, pages 425 *
吕毅, 郭雯飞, 倪捷儿, 杨贤强: "茶氨酸的生理作用及合成", 茶叶科学, no. 01, pages 1 - 5 *
唐颢;唐劲驰;凌彩金;苗爱清;王秋霜;孙世利;: "茶氨酸的制备与生理活性研究进展", 中国茶叶, no. 01, pages 18 - 21 *
王庆利等: "茶氨酸对脑缺血损伤大鼠自由基代谢的影响", 实用医学杂志, vol. 24, no. 11, pages 1898 - 1900 *
王玉芬;李春雨;秦志祥;唐振山;赵中夫;贾晋太;: "茶氨酸对脑缺血再灌注损伤保护作用的实验研究", 中华神经医学杂志, no. 06, pages 562 - 565 *

Similar Documents

Publication Publication Date Title
CN104367587B (en) Application of the nicotinamide mononucleotide after rush cerebral ischemia is prepared in nerve regneration drug
CN104072584B (en) Peptides for promoting angiogenesis and a use thereof
CN116672332A (en) Application of L-theanine in preparation of angiogenesis promoter
CN113897337A (en) Method for regulating polarization state of macrophage
CN111450089A (en) Application of Bepridil or KB-R7943 in preparation of medicine for treating melanoma
EP4275703A1 (en) Use of pd1 inhibitor in preparation of cardiac fibroblast transdifferentiation inhibitor
CN108066337B (en) Application of the KB-R7943 or Bepridil in the drug of preparation treatment glioma
Schwartz et al. Enhancement of small intestine absorption by intraluminal gastrin
CN110437311A (en) A kind of polypeptide and its application
CN113577083B (en) Application of small molecule compound combination in preparation of medicine for preventing and treating retina injury diseases
CN108865991A (en) A kind of preparation process of culture medium that simulating diabetes inflammatory microenvironment
CN112641794B (en) Application of dipsacus asperoides saponin B in preparing medicine for preventing and treating vascular diseases
Liska et al. Inhibition of transforming growth factor beta-1 augments liver regeneration after partial portal vein ligation in a porcine experimental model
CN112210891A (en) Axitinib-loaded nanofiber membrane, preparation method thereof and application thereof in postoperative adhesion prevention
CN109966274B (en) Application of guaiol in preparation of medicine for inhibiting tumor-related M2-type macrophages
CN111888348A (en) Application of glucose transporter 1 inhibitor WZB117 in preparation of drugs for treating cystic echinococcosis
CN110327317A (en) Application of the alkannin in the drug for preparing anti-rotavirus infection
CN104478780B (en) Acylpyrrole small-molecular organic compound, derivatives of organic compound as well as application and preparation method of acylpyrrole small-molecular organic compound and derivatives of organic compound
CN108524939B (en) Mitochondrial complex I reversible inhibitor combines the purposes for preparing ischemical reperfusion injury protection drug with active oxygen scavenger
CN114642668B (en) New pharmaceutical application of latanoprost
CN102389408B (en) Application of saturated amine compound in preparing medicament for treating ischemic diseases
CN112603914B (en) New application of phenylephrine hydrochloride medicament
CN114380680B (en) Flavonoid compound and application thereof
CN103083323A (en) Application of fasudil hydrochloride in preparation of medicament for promoting in-vivo survival and repair of mesenchymal stem cells and preparation of fasudil hydrochloride
WO2021129535A1 (en) Application of endoderm stem cells in prevention and/or treatment of liver immune disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination